PIK3CA Mutations Negatively Affect Survival in Trastuzumab-Treated HER2-Positive Breast Cancer

A study confirmed that PIK3CA mutations negatively affect survival in patients with HER2-positive breast cancer treated with the anti-HER2 therapy trastuzumab.

Source: Cancer Network - May 6, 2013 Category: Cancer & Oncology Source Type: news